Efficacy and safety of thalidomide (1 vs 2 mg/kg per day) in transfusion-dependent thalassemia: a noninferiority trial

Blood Advances · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles